Pharmaceutical - Johnson & Johnson

Filter

Current filters:

Johnson & Johnson

Popular Filters

201 to 225 of 261 results

EU Commission OKs J&J's buy of Synthes, but with conditions

22-04-2012

The European Commission last week cleared under the EU Merger Regulation the proposed $21.3 billion acquisition…

Johnson & JohnsonMergers & AcquisitionsPharmaceuticalSynthes

Bristol-Myers expands hepatitis C accord with Medivir and Janssen

18-04-2012

Swedish infectious disease drug developer Medivir AB (OMX: MVIR) said yesterday that its development…

Anti-viralsBristol-Myers SquibbdaclatasvirJanssenJohnson & JohnsonLicensingMedivirPharmaceuticalResearch

Johnson & Johnson 1st-qtr earnings up 12.5% but sales flat

18-04-2012

US health care giant Johnson & Johnson (NYSE: JNJ) posted first-quarter 2012 financial results in line…

FinancialJohnson & JohnsonPharmaceutical

News briefs on Janssen, Bayer and Merck KGaA/Threshold

12-04-2012

In the USA, the Arkansas jury found that the Janssen unit of US health care giant Johnson & Johnson (NYSE:…

BayerFinancialJanssenJohnson & JohnsonLegalMerck KGaAPharmaceuticalRegulationRisperdalThreshold PharmaceuticalsXarelto

Senior exec changes actual or sought at Johnson & Johnson, AstraZeneca and Optimer

10-04-2012

US health care giant Johnson & Johnson (NYSE: JNJ) said on Monday that Sherilyn (Sheri) McCoy, vice chairman…

AstraZenecaJohnson & JohnsonManagementOptimer PharmaceuticalsPharmaceutical

Forest Labs buys Bystolic rights from Janssen for $357 million

03-04-2012

Forest Laboratories, (NYSE: FRX) says it has acquired all US patents and other US and Canadian intellectual…

BystolicCardio-vascularForest LaboratoriesJanssen PharmaceuticaJohnson & JohnsonLicensingNorth AmericaPharmaceuticalSavella

Strong results for Bayer's Xarelto in treating pulmonary blood clots

27-03-2012

German drugs and crops sciences group Bayer (BAY: DE), and partner Janssen, part of US health care major…

BayerCardio-vascularJanssenJohnson & JohnsonPharmaceuticalRegulationResearchRespiratory and PulmonaryXarelto

Index Ventures debuts new Life Sciences Fund, partnered by GSK and J&J

21-03-2012

Index Ventures says it has launched its first fund solely dedicated to making investments in the life…

BiotechnologyFinancialGlaxoSmithKlineIndex VenturesJanssenJohnson & JohnsonPharmaceutical

Tapentadol ER has advantages over Lyrica in reducing diabetic neuropathy pain intensity

21-03-2012

Surveyed US neurologists and managed care organization (MCO) pharmacy directors agree that reducing pain…

DepomedGraliseJohnson & JohnsonLyricaMarkets & MarketingNeurologicalNorth AmericaPfizerPharmaceuticaltapentadol

Caelyx and Ceplene manufacturing should be moved, says EMA

18-03-2012

The European Medicines Agency has recommended that the manufacturing processes for the anticancer medicines…

Boehringer IngelheimCaelyxCepleneEpiCeptJanssen-CilagJohnson & JohnsonOncologyPharmaceuticalRegulationRespiratory and Pulmonary

Positive NICE news for Gilenya for MS and Incivo for hep C

16-03-2012

There was good news from the UK drugs watchdog the Institute for Health and Clinical Excellence (NICE)…

Anti-viralsEuropeGilenyaIncivoJanssen-CilagJohnson & JohnsonNeurologicalNovartisPharmaceuticalPricingRegulation

Unblinded Zytiga study meets endpoints in prostate cancer

09-03-2012

Janssen Research & Development, a subsidiary of US health care giant Johnson & Johnson (NYSE: JNJ), has…

JanssenJohnson & JohnsonOncologyPharmaceuticalResearchZytiga

Bayer and J&J’s Xarelto gets US Priority Review for new indication

29-02-2012

The US Food and Drug Administration has granted Priority Review designation to the supplemental New Drug…

BayerCardio-vascularJanssenJohnson & JohnsonNorth AmericaPharmaceuticalRegulationXarelto

Alex Gorsky named as CEO of Johnson & Johnson

22-02-2012

Troubled US health care giant Johnson & Johnson (NYSE: JNJ) last night announced that its board of directors…

Johnson & JohnsonManagementPharmaceutical

Pharmacyclics and Janssen’s PCI-32765 set to be gold standard for its blood cancer indication

19-02-2012

Based on clinical data and the opinions of interviewed thought leaders, Pharmacyclics (Nasdaq: PCYC)…

BiotechnologyGlobalJanssen BiotechJohnson & JohnsonMarkets & MarketingOncologyPharmaceuticalPharmacyclics

Four new drugs will change prostate cancer care, says US expert

19-02-2012

After a decade and a half of near stagnation, four new drugs could help make advanced prostate cancer…

AlgetaAlpharadinAmgenBavarian NordicBayerJohnson & JohnsonOncologyPharmaceuticalProstvacXgevaZytiga

Johnson & Johnson in deal with Australia University for spider venom pain research

16-02-2012

UniQuest, Australian University of Queensland’s (UQ) main research commercialization company, says…

Johnson & JohnsonNeurologicalPharmaceuticalResearch

NICE issues negative guidance for Zytiga

02-02-2012

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has issued new draft…

EuropeJanssenJohnson & JohnsonOncologyPharmaceuticalPricingRegulationZytiga

Janssen drops deal with Orexo for OX-CLI/OX-ESI

01-02-2012

US health care major Johnson & Johnson INYSE: JNJ) subsidiary Janssen has decided to end research collaboration…

FinancialJanssenJohnson & JohnsonLicensingOrexo ABPharmaceuticalRespiratory and Pulmonary

Johnson & Johnson beats forecast despite profits slump

25-01-2012

US health care giant Johnson & Johnson (NYSE: JNJ) has announced sales of $16.3 billion for the fourth…

FinancialJohnson & JohnsonPharmaceutical

Germany’s IQWiG sees added benefits for Incivo

24-01-2012

In an early benefit assessment pursuant to Germany’s Act on the Reform of the Market for Medicinal…

Anti-viralsEuropeIncivekIncivoJanssenJohnson & JohnsonPharmaceuticalPricingRegulationVertex

201 to 225 of 261 results

Back to top